CHRS vs RCUS
CHRS: Coherus Oncology is a commercial-stage immuno-oncology company developing next-generation PD-1 inhibitors and checkpoint inhibitors for difficult-to-treat cancers including nasopharyngeal carcinoma, hepatocellular carcinoma, and head & neck squamous cell carcinoma. RCUS: A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials.
Side-by-side fundamentals
| Metric | CHRS | RCUS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.43 | $29.97 | |
| Market cap as of 2026-07-23 | $227M | $3.7B | |
| P/E as of 2026-07-23 | 1.22 | n/a | |
| PEG as of 2026-07-23 | -0.12 | n/a | |
| Net margin as of 2026-07-23 | +397.3% | -156.4% | CHRS higher |
| Gross margin as of 2026-07-23 | +68.1% | n/a | |
| Operating margin as of 2026-07-23 | -366.6% | -168.6% | RCUS higher |
| ROE as of 2026-07-23 | +214.6% | -69.0% | CHRS higher |
| ROA as of 2026-07-23 | +50.3% | -35.3% | CHRS higher |
| Debt / equity as of 2026-07-23 | 0.66 | 0.19 | RCUS lower |
| Revenue growth (YoY) as of 2026-07-23 | -76.3% | -15.1% | RCUS higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -4.6% | |
| Beta as of 2026-07-23 | 0.93 | 0.81 | |
| 1-year return as of 2026-07-22 close | +55.1% | +218.4% | RCUS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.